FDA Publishes Final Guidance on Computer Software Assurance (CSA)

• Focus on high-risk features that impact patient safety and product quality

• Right-sized documentation – evidence proportionate to risk

• Use of both scripted and unscripted testing for efficiency and flexibility

• Greater reliance on vendor assurance activities and modern quality practices

While this guidance is aimed at medical device production and quality systems, the principles perfectly align with clinical trial software validation.

At Flex Databases, we are already applying these concepts:

✅ Risk-based validation aligned with GAMP 5 and regulatory expectations
✅ Efficient testing strategies focused on functions that matter most
✅ Robust documentation and audit readiness without unnecessary overhead
✅ Client partnership to ensure systems remain compliant in an evolving regulatory landscape

Our approach ensures that clients benefit from FDA-aligned best practices today, making compliance easier while maintaining the highest standards of data integrity and patient safety.

🔗 Link to FDA guidance